{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T23:54:36Z","timestamp":1767138876168,"version":"build-2238731810"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Die Behandlung von erh\u00f6hten Lipidwerten spielt in der Atherosklerosepr\u00e4vention eine zentrale Rolle, wobei der Low-Density-Lipoprotein(LDL)-Cholesterin-Senkung mit Statinen und, wenn nicht ausreichend, mit Ezetimib, Bempedoins\u00e4ure und Inhibitoren der Proproteinkonvertase Subtilisin\/Kexin Typ 9 (PCSK9) die gr\u00f6\u00dfte Bedeutung zukommt. Auch wenn Lebensstilma\u00dfnahmen das kardiovaskul\u00e4re Risiko stark beeinflussen k\u00f6nnen, spielen sie f\u00fcr die Absenkung des LDL-Cholesterin-Werts nur eine untergeordnete Rolle. F\u00fcr die Entscheidung, ob, und ggf. wie, intensiv eine Lipidsenkung durchgef\u00fchrt werden soll, ist das kardiovaskul\u00e4re Absolutrisiko entscheidend. Die Zielwerte sind in den letzten Jahren aufgrund der Ergebnisse von Interventionsstudien weiter abgesenkt worden. Bei Patienten mit sehr hohem Risiko (z.\u202fB. Patienten mit manifester Atheroskleroseerkrankung) sollten ein LDL-Cholesterin-Wert &lt;\u202f55\u202fmg\/dl (&lt;\u202f1,4\u202fmmol\/l; Umrechnung: [mg\/dl]\u202f\u2022\u20090,02586\u202f=\u2009[mmol\/l]) und mindestens eine Halbierung des Ausgangswertes angestrebt werden. Hinsichtlich erh\u00f6hter Triglyzeridwerte, entweder isoliert oder bei gleichzeitiger Erh\u00f6hung des LDL-Cholesterin-Werts, sind die Behandlungsziele weniger klar definiert, obwohl auch erh\u00f6hte Triglyzeridspiegel kausal mit Atheroskleroseereignissen verkn\u00fcpft sind. Lebensstilma\u00dfnahmen k\u00f6nnen die Triglyzeridspiegel deutlich absenken und sind oft effektiver als spezifische Triglyzeridsenker wie Fibrate und Omega-3-Fetts\u00e4uren. Neue Lipidsenker zur Behandlung bei stark erh\u00f6hten Triglyzerid- und erh\u00f6hten Lipoprotein(a)Werten sind in der Entwicklung, m\u00fcssen ihren Nutzen aber erst in Endpunktstudien belegen.<\/jats:p>","DOI":"10.1007\/s00108-023-01536-8","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T06:02:10Z","timestamp":1686808930000},"page":"611-621","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Update Lipidologie","Update lipidology"],"prefix":"10.1007","volume":"64","author":[{"given":"Klaus G.","family":"Parhofer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"issue":"12","key":"1536_CR1","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.metabol.2014.08.010","volume":"63","author":"L Wu","year":"2014","unstructured":"Wu\u00a0L, Parhofer\u00a0KG (2014) Diabetic dyslipidemia. Metabolism 63(12):1469\u20131479","journal-title":"Metabolism"},{"issue":"1","key":"1536_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","volume":"41","author":"U Laufs","year":"2020","unstructured":"Laufs\u00a0U, Parhofer\u00a0KG, Ginsberg\u00a0HN et\u00a0al (2020) Clinical review on triglycerides. Eur Heart\u00a0J 41(1):99\u2013109c","journal-title":"Eur Heart J"},{"issue":"1","key":"1536_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach\u00a0F, Baigent\u00a0C, Catapano\u00a0AL et\u00a0al (2020) 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart\u00a0J 41(1):111\u2013188","journal-title":"Eur Heart J"},{"issue":"25","key":"1536_CR4","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1093\/eurheartj\/ehw152","volume":"37","author":"BG Nordestgaard","year":"2016","unstructured":"Nordestgaard\u00a0BG, Langsted\u00a0A, Mora\u00a0S et al (2016) Fasting is not routinely required for determination of a\u00a0lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points\u2014a joint consensus statement from the European atherosclerosis society and European federation of clinical chemistry and laboratory medicine. Eur Heart\u00a0J 37(25):1944\u20131958","journal-title":"Eur Heart J"},{"issue":"12","key":"1536_CR5","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1001\/jama.2012.366","volume":"307","author":"SM Boekholdt","year":"2012","unstructured":"Boekholdt\u00a0SM, Arsenault\u00a0BJ, Mora\u00a0S et al (2012) Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a\u00a0meta-analysis. JAMA 307(12):1302\u20131309","journal-title":"JAMA"},{"issue":"32","key":"1536_CR6","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1093\/eurheartj\/ehx163","volume":"38","author":"CM Madsen","year":"2017","unstructured":"Madsen\u00a0CM, Varbo\u00a0A, Nordestgaard\u00a0BG (2017) Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart\u00a0J 38(32):2478\u20132486","journal-title":"Eur Heart J"},{"issue":"3","key":"1536_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1080\/00365513.2020.1716266","volume":"80","author":"A Kallner","year":"2020","unstructured":"Kallner A, Petersmann A, Nauck M et\u00a0al (2020) Measurement repeatability profiles of eight frequently requested measurands in clinical chemistry determined by duplicate measurements of patient samples. Scand J Clin Lab Invest 80(3):202\u2013209. https:\/\/doi.org\/10.1080\/00365513.2020.1716266","journal-title":"Scand J Clin Lab Invest"},{"key":"1536_CR8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1161\/01.cir.31.3.321","volume":"31","author":"DS Fredrickson","year":"1965","unstructured":"Fredrickson DS, Lees RS (1965) A system for phenotyping hyperlipoproteinemia. Circulation 31:321\u2013327. https:\/\/doi.org\/10.1161\/01.cir.31.3.321","journal-title":"Circulation"},{"issue":"5","key":"1536_CR9","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","volume":"63","author":"PR Kamstrup","year":"2014","unstructured":"Kamstrup\u00a0PR, Tybjaerg-Hansen\u00a0A, Nordestgaard\u00a0BG (2014) Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J\u00a0Am Coll Cardiol 63(5):470\u2013477","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1536_CR10","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/MOL.0000000000000855","volume":"33","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg\u00a0F, Mora\u00a0S, Stroes\u00a0ESG (2022) Consensus and guidelines on lipoprotein(a)\u2014seeing the forest through the trees. Curr Opin Lipidol 33(6):342\u2013352","journal-title":"Curr Opin Lipidol"},{"issue":"12","key":"1536_CR11","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1001\/jamainternmed.2016.6875","volume":"176","author":"SB Pedersen","year":"2016","unstructured":"Pedersen\u00a0SB, Langsted\u00a0A, Nordestgaard\u00a0BG (2016) Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis. JAMA Intern Med 176(12):1834\u20131842","journal-title":"JAMA Intern Med"},{"issue":"9841","key":"1536_CR12","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","volume":"380","author":"BF Voight","year":"2012","unstructured":"Voight\u00a0BF, Peloso\u00a0GM, Orho-Melander\u00a0M et al (2012) Plasma HDL cholesterol and risk of myocardial infarction: a\u00a0mendelian randomisation study. Lancet 380(9841):572\u2013580","journal-title":"Lancet"},{"issue":"9841","key":"1536_CR13","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","volume":"380","author":"B Mihaylova","year":"2012","unstructured":"Mihaylova\u00a0B, Emberson\u00a0J, Blackwell\u00a0L et al (2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380(9841):581\u2013590","journal-title":"Lancet"},{"issue":"25","key":"1536_CR14","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy\u00a0SM, Stone\u00a0NJ, Bailey\u00a0AL et\u00a0al (2019) 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines. Circulation 139(25):e1082\u2013e1143","journal-title":"Circulation"},{"issue":"4","key":"1536_CR15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/pds.1297","volume":"16","author":"L Wei","year":"2007","unstructured":"Wei\u00a0L, MacDonald\u00a0TM, Watson\u00a0AD et\u00a0al (2007) Effectiveness of two statin prescribing strategies with respect to adherence and cardiovascular outcomes: observational study. Pharmacoepidemiol Drug Saf 16(4):385\u2013392","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"24","key":"1536_CR16","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1056\/NEJMoa1605086","volume":"375","author":"AV Khera","year":"2016","unstructured":"Khera\u00a0AV, Emdin\u00a0CA, Drake\u00a0I et\u00a0al (2016) Genetic risk, adherence to a\u00a0healthy lifestyle, and coronary disease. N\u00a0Engl J Med 375(24):2349\u20132358","journal-title":"N Engl J Med"},{"issue":"2","key":"1536_CR17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1161\/01.cir.69.2.325","volume":"69","author":"RI Levy","year":"1984","unstructured":"Levy RI, Brensike JF, Epstein SE, Kelsey SF, Passamani ER, Richardson JM, Loh IK, Stone NJ, Aldrich RF, Battaglini JW et al (1984) The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study. Circulation 69(2):325\u2013337. https:\/\/doi.org\/10.1161\/01.cir.69.2.325","journal-title":"Circulation"},{"issue":"10059","key":"1536_CR18","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","volume":"388","author":"R Collins","year":"2016","unstructured":"Collins\u00a0R, Reith\u00a0C, Emberson\u00a0J et\u00a0al (2016) Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388(10059):2532\u20132561","journal-title":"Lancet"},{"issue":"25","key":"1536_CR19","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon\u00a0CP, Blazing\u00a0MA, Giugliano\u00a0RP et\u00a0al (2015) Ezetimibe added to statin therapy after acute coronary syndromes. N\u00a0Engl J Med 372(25):2387\u20132397","journal-title":"N Engl J Med"},{"issue":"15","key":"1536_CR20","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","volume":"388","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Lincoff AM, Brennan D et al (2023) Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N\u00a0Engl J Med 388(15):1353\u20131364. https:\/\/doi.org\/10.1056\/NEJMoa2215024","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"1536_CR21","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine\u00a0MS, Giugliano\u00a0RP, Keech\u00a0AC et\u00a0al (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N\u00a0Engl J Med 376(18):1713\u20131722","journal-title":"N Engl J Med"},{"issue":"22","key":"1536_CR22","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz\u00a0GG, Steg\u00a0PG, Szarek\u00a0M et\u00a0al (2018) Alirocumab and cardiovascular outcomes after acute coronary syndrome. N\u00a0Engl J Med 379(22):2097\u20132107","journal-title":"N Engl J Med"},{"issue":"8","key":"1536_CR23","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1161\/CIRCULATIONAHA.118.034309","volume":"138","author":"MS Sabatine","year":"2018","unstructured":"Sabatine\u00a0MS, De Ferrari\u00a0GM, Giugliano\u00a0RP et\u00a0al (2018) Clinical benefit of evolocumab by severity and extent of coronary artery disease. Circulation 138(8):756\u2013766","journal-title":"Circulation"},{"issue":"22","key":"1536_CR24","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/eurheartj\/ehx648","volume":"39","author":"U Landmesser","year":"2018","unstructured":"Landmesser U, Chapman MJ, Stock JK et\u00a0al (2018) Update of ESC\/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin\/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur Heart\u00a0J 39(22):2105. https:\/\/doi.org\/10.1093\/eurheartj\/ehx648","journal-title":"Eur Heart\u00a0J"},{"issue":"3","key":"1536_CR25","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","volume":"251","author":"Lipid Research Clinics Program","year":"1984","unstructured":"Lipid Research Clinics Program (1984) The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 251(3):351\u2013364","journal-title":"JAMA"},{"issue":"17","key":"1536_CR26","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.2174\/1381612811319170020","volume":"19","author":"N Katsiki","year":"2013","unstructured":"Katsiki\u00a0N, Nikolic\u00a0D, Montalto\u00a0G et\u00a0al (2013) The role of fibrate treatment in dyslipidemia: an overview. Curr Pharm Des 19(17):3124\u20133131","journal-title":"Curr Pharm Des"},{"key":"1536_CR27","first-page":"CD009580","volume":"10","author":"D Wang","year":"2015","unstructured":"Wang\u00a0D, Liu\u00a0B, Tao\u00a0W et\u00a0al (2015) Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Database Syst Rev 10:CD9580","journal-title":"Cochrane Database Syst Rev"},{"issue":"21","key":"1536_CR28","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","volume":"387","author":"A Das Pradhan","year":"2022","unstructured":"Das Pradhan\u00a0A, Glynn\u00a0RJ, Fruchart\u00a0JC et\u00a0al (2022) Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N\u00a0Engl J Med 387(21):1923\u20131934","journal-title":"N Engl J Med"},{"issue":"3","key":"1536_CR29","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1001\/jamacardio.2017.5205","volume":"3","author":"T Aung","year":"2018","unstructured":"Aung\u00a0T, Halsey\u00a0J, Kromhout\u00a0D et al (2018) Associations of omega\u20113 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77917 individuals. JAMA Cardiol 3(3):225\u2013234","journal-title":"JAMA Cardiol"},{"issue":"16","key":"1536_CR30","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","volume":"379","author":"L Bowman","year":"2018","unstructured":"ASCEND Study Collaborative Group, Bowman\u00a0L, Mafham\u00a0M et al (2018) Effects of n\u20113 fatty acid supplements in diabetes mellitus. N\u00a0Engl J Med 379(16):1540\u20131550","journal-title":"N Engl J Med"},{"issue":"1","key":"1536_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1811403","volume":"380","author":"JE Manson","year":"2019","unstructured":"Manson\u00a0JE, Cook\u00a0NR, Lee\u00a0IM et al (2019) Marine n\u20113 fatty acids and prevention of cardiovascular disease and cancer. N\u00a0Engl J Med 380(1):23\u201332","journal-title":"N Engl J Med"},{"issue":"1","key":"1536_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt\u00a0DL, Steg\u00a0PG, Miller\u00a0M et\u00a0al (2019) Cardiovascular risk reduction with Icosapent ethyl for hypertriglyceridemia. N\u00a0Engl J Med 380(1):11\u201322","journal-title":"N Engl J Med"},{"issue":"6","key":"1536_CR33","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","volume":"381","author":"JL Witztum","year":"2019","unstructured":"Witztum\u00a0JL, Gaudet\u00a0D, Freedman\u00a0SD et\u00a0al (2019) Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N\u00a0Engl J Med 381(6):531\u2013542","journal-title":"N Engl J Med"},{"issue":"8","key":"1536_CR34","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","volume":"383","author":"FJ Raal","year":"2020","unstructured":"Raal\u00a0FJ, Rosenson\u00a0RS, Reeskamp\u00a0LF et\u00a0al (2020) Evinacumab for homozygous familial hypercholesterolemia. N\u00a0Engl J Med 383(8):711\u2013720","journal-title":"N Engl J Med"},{"issue":"9860","key":"1536_CR35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0140-6736(12)61845-5","volume":"381","author":"FJ Raal","year":"2013","unstructured":"Raal\u00a0FJ (2013) Lomitapide for homozygous familial hypercholesterolaemia. Lancet 381(9860):7\u20138","journal-title":"Lancet"},{"issue":"2","key":"1536_CR36","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.pathol.2018.10.016","volume":"51","author":"E Waldmann","year":"2019","unstructured":"Waldmann\u00a0E, Parhofer\u00a0KG (2019) Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a). Pathology 51(2):227\u2013232","journal-title":"Pathology"},{"issue":"3","key":"1536_CR37","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas\u00a0S, Karwatowska-Prokopczuk\u00a0E, Gouni-Berthold\u00a0I et al (2020) Lipoprotein(a) reduction in persons with cardiovascular disease. N\u00a0Engl J Med 382(3):244\u2013255","journal-title":"N Engl J Med"},{"issue":"34","key":"1536_CR38","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren\u00a0FLJ, Mach\u00a0F, Smulders\u00a0YM et\u00a0al (2021) 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart\u00a0J 42(34):3227\u20133337","journal-title":"Eur Heart J"},{"issue":"3","key":"1536_CR39","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s40801-019-0158-0","volume":"6","author":"KG Parhofer","year":"2019","unstructured":"Parhofer KG, Von Stritzky B, Pietschmann N et al (2019) PEARL: a\u00a0non-interventional study of real-world alirocumab use in German clinical practice. Clin Res Cardiol 6(3):115\u2013123. https:\/\/doi.org\/10.1007\/s40801-019-0158-0","journal-title":"Clin Res Cardiol"},{"issue":"11","key":"1536_CR40","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","volume":"28","author":"KK Ray","year":"2021","unstructured":"Ray\u00a0KK, Molemans\u00a0B, Schoonen\u00a0WM et al (2021) EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol 28(11):1279\u20131289","journal-title":"Eur J Prev Cardiol"},{"issue":"49","key":"1536_CR41","first-page":"825","volume":"116","author":"KG Parhofer","year":"2019","unstructured":"Parhofer\u00a0KG, Laufs\u00a0U (2019) The diagnosis and treatment of hypertriglyceridemia. Dtsch Arztebl Int 116(49):825\u2013832","journal-title":"Dtsch Arztebl Int"},{"key":"1536_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2016.10.002","volume":"23","author":"E Stroes","year":"2017","unstructured":"Stroes\u00a0E, Moulin\u00a0P, Parhofer\u00a0KG et\u00a0al (2017) Diagnostic algorithm for familial chylomicronemia syndrome. Atheroscler Suppl 23:1\u20137","journal-title":"Atheroscler Suppl"}],"updated-by":[{"DOI":"10.1007\/s00108-023-01641-8","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000}}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01536-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-023-01536-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01536-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T11:04:35Z","timestamp":1704279875000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-023-01536-8"}},"subtitle":["Evidenzbasierte Behandlung von Fettstoffwechselst\u00f6rungen","Evidence-based treatment of dyslipidemia"],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1536"],"URL":"https:\/\/doi.org\/10.1007\/s00108-023-01536-8","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]},"assertion":[{"value":"4 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Zu diesem Beitrag wurde ein Erratum ver\u00f6ffentlicht:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00108-023-01641-8","URL":"https:\/\/doi.org\/10.1007\/s00108-023-01641-8","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"K.G.\u00a0Parhofer: Vortragshonorare, Honorare f\u00fcr Advisory Board T\u00e4tigkeit, Honorare f\u00fcr DMC-T\u00e4tigkeit und\/oder Forschungsunterst\u00fctzung von folgenden Unternehmen: Aegerion, Akcea, Amgen, Amryt, Berlin-Chemie, Boehringer-Ingelheim, MSD, Novartis, Pfizer, Regeneron, Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}